Brief: Gensight Biologics: estimates 14 mln euros needed to finance activities until July, could eye merger

Gensight Biologics SA

27/12/2023 06:36

Dec 27 (Reuters) - Gensight Biologics Sa  SIGHT.PA :
    * GENSIGHT BIOLOGICS PROVIDES BUSINESS AND FINANCIAL UPDATE
    * DISCUSSING WITH EXISTING AND POTENTIAL NEW SHAREHOLDERS TO
FINANCE ITS ACTIVITIES FROM MID-FEBRUARY TO Q3 2024
    * ADVANCING ON NUMBER OF DISCUSSIONS WITH POTENTIAL PARTNERS
ON
STRATEGIC OPPORTUNITIES, INCLUDING POSSIBLE MERGER, ACQUISITION
OR LICENSING DEAL
    * UK MHRA COULD ACCEPT A MARKETING AUTHORISATION APPLICATION
FOR
LUMEVOQ(®)
    * EXTENDED CASH RUNWAY TO MID-FEBRUARY 2024
    * ONGOING DISCUSSIONS TO BRIDGE AAC RESUMPTION IN FRANCE IN
Q3
2024
    * ESTIMATES IT WILL REQUIRE APPROXIMATELY EUR 14 MILLION TO
FINANCE ITS ACTIVITIES UNTIL JULY 2024

Source text for Eikon:  ID:nBwbrfH3sa 
Further company coverage:  SIGHT.PA 

 (Reporting by Sudip Kar-Gupta)
 ((sudip.kargupta@thomsonreuters.com;))